Kindeva appoints David Stevens as new CEO
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
Subscribe To Our Newsletter & Stay Updated